Aileron Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference

AUSTIN, Texas, July 30, 2024 -- Aileron Therapeutics, Inc. (NASDAQ: ALRN), a biopharmaceutical firm dedicated to developing innovative treatments for orphan pulmonary and fibrosis conditions, has announced that its CEO, Brian Windsor, Ph.D., will be presenting at the Canaccord Genuity 44th Annual Growth Conference. The presentation is scheduled for Tuesday, August 13, 2024, at 4:00 p.m. EDT in Boston, MA. 

A live broadcast of Windsor's presentation will be accessible online, and a replay will be available for 90 days post-event.

Aileron Therapeutics is at the forefront of creating breakthrough medications to tackle severe unmet medical needs, particularly in the areas of orphan pulmonary and fibrosis-related diseases. The company's premier product candidate, LTI-03, is a synthetic peptide designed with a dual purpose: supporting the survival of alveolar epithelial cells and impeding profibrotic signaling. This innovative treatment is currently undergoing Phase 1b clinical trials aimed at addressing idiopathic pulmonary fibrosis, a condition known for its severe and progressive nature.

In addition to LTI-03, Aileron is developing another promising treatment, LTI-01. This product is a proenzyme that has successfully completed both Phase 1b and Phase 2a clinical trials. LTI-01 targets loculated pleural effusions, a complex medical condition involving fluid accumulation between the layers of tissue lining the lungs and chest cavity. Notably, LTI-01 has been granted Orphan Drug Designation in both the United States and the European Union, as well as Fast Track Designation in the United States, highlighting its potential to address critical medical needs swiftly and effectively.

Aileron Therapeutics continues to leverage its expertise in biopharmaceutical research to develop first-in-class medicines that could transform the treatment landscape for patients suffering from rare and debilitating pulmonary and fibrosis conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!